MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/190/0.1/20.09.24 Stock

Warrant

DE000ME9ZMT2

Market Closed - Börse Stuttgart 12:50:29 2024-06-28 EDT
0.065 EUR -2.99% Intraday chart for MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/190/0.1/20.09.24
Current month+25.00%
1 month+32.65%
Date Price Change
24-06-28 0.065 -2.99%
24-06-27 0.067 -5.63%
24-06-26 0.071 -19.32%
24-06-25 0.088 +44.26%
24-06-24 0.061 -4.69%

Delayed Quote Börse Stuttgart

Last update June 28, 2024 at 12:50 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying NOVO NORDISK A/S
Issuer Morgan Stanley
WKN ME9ZMT
ISINDE000ME9ZMT2
Date issued 2024-03-11
Strike 190 $
Maturity 2024-09-20 (83 Days)
Parity 10 : 1
Emission price 0.31
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.216
Lowest since issue 0.031
Delta0.07x
Omega 14.13
Premium33.58x
Gearing211.54x
Moneyness 0.7513
Difference Strike 47.26 $
Difference Strike %+24.87%
Spread 0.006
Spread %9.09%
Theoretical value 0.0630
Implied Volatility 35.96 %
Total Loss Probability 95.29 %
Intrinsic value 0.000000
Present value 0.0630
Break even 190.67 €
Theta-0.01x
Vega0.01x
Rho0x

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
More about the company

Ratings for Novo Nordisk A/S

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Consensus: Novo Nordisk A/S

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006 DKK
Average target price
949.7 DKK
Spread / Average Target
-5.56%
Consensus